Zealand Pharma A/S (OTCMKTS:ZLDPF) Rating Increased to Strong-Buy at Barclays

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) was upgraded by investment analysts at Barclays to a "strong-buy" rating in a research report issued on Monday,Zacks.com reports.

Separately, BNP Paribas raised Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, July 1st. One investment analyst has rated the stock with a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Strong Buy".

Zealand Pharma A/S Stock Performance

Shares of OTCMKTS ZLDPF traded down $2.00 during trading hours on Monday, hitting $57.56. 165 shares of the company's stock were exchanged, compared to its average volume of 867. Zealand Pharma A/S has a 1-year low of $54.95 and a 1-year high of $141.74. The company has a debt-to-equity ratio of 0.03, a current ratio of 25.10 and a quick ratio of 25.07. The stock has a market capitalization of $4.09 billion, a price-to-earnings ratio of -23.12 and a beta of 0.68. The company's 50-day moving average price is $63.80 and its 200-day moving average price is $78.79.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.10. Zealand Pharma A/S had a negative return on equity of 13.40% and a negative net margin of 2,127.09%. The business had revenue of $1.14 million during the quarter, compared to analysts' expectations of $248.61 million. On average, sell-side analysts expect that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.